Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people
-
Published:2024-01-09
Issue:
Volume:
Page:
-
ISSN:1618-7598
-
Container-title:The European Journal of Health Economics
-
language:en
-
Short-container-title:Eur J Health Econ
Author:
Sach Tracey H.ORCID, Onoja Mary, Clarke Holly, Santer MiriamORCID, Muller IngridORCID, Becque TaekoORCID, Stuart BethORCID, Hooper JulieORCID, Steele MaryORCID, Wilczynska Sylvia, Ridd Matthew J.ORCID, Roberts Amanda, Ahmed Amina, Yardley LucyORCID, Little PaulORCID, Greenwell KateORCID, Sivyer KatyORCID, Nuttall Jacqui, Griffiths Gareth, Lawton SandraORCID, Langan Sinéad M.ORCID, Howells LauraORCID, Leighton PaulORCID, Williams Hywel C.ORCID, Thomas Kim S.ORCID
Abstract
Abstract
Objective
To estimate the cost-effectiveness of online behavioral interventions (EczemaCareOnline.org.uk) designed to support eczema self-care management for parents/carers and young people from an NHS perspective.
Methods
Two within-trial economic evaluations, using regression-based approaches, adjusting for baseline and pre-specified confounder variables, were undertaken alongside two independent, pragmatic, parallel group, unmasked randomized controlled trials, recruiting through primary care. Trial 1 recruited 340 parents/carers of children aged 0–12 years and Trial 2 337 young people aged 13–25 years with eczema scored ≥ 5 on Patient-Oriented Eczema Measure (POEM). Participants were randomized (1:1) to online intervention plus usual care or usual care alone. Resource use, collected via medical notes review, was valued using published unit costs in UK £Sterling 2021. Quality-of-life was elicited using proxy CHU-9D in Trial 1 and self-report EQ-5D-5L in Trial 2.
Results
The intervention was dominant (cost saving and more effective) with a high probability of cost-effectiveness (> 68%) in most analyses. The exception was the complete case cost–utility analysis for Trial 1 (omitting participants with children aged < 2), with adjusted incremental cost savings of -£34.15 (95% CI – 104.54 to 36.24) and incremental QALYs of – 0.003 (95% CI – 0.021 to 0.015) producing an incremental cost per QALY of £12,466. In the secondary combined (Trials 1 and 2) cost-effectiveness analysis, the adjusted incremental cost was -£20.35 (95% CI – 55.41 to 14.70) with incremental success (≥ 2-point change on POEM) of 10.3% (95% CI 2.3–18.1%).
Conclusion
The free at point of use online eczema self-management intervention was low cost to run and cost-effective.
Trial registration
This trial was registered prospectively with the ISRCTN registry (ISRCTN79282252). URL www.EczemaCareOnline.org.uk.
Funder
Programme Grants for Applied Research
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference36 articles.
1. Williams, H.C., Grindlay, D.J.C.: What’s new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1. Definitions, causes and consequences of eczema. Clin. Exp. Dermatol. 35(1), 12–15 (2010). https://doi.org/10.1111/j.1365-2230.2009.03733.x 2. Kemp, A.S.: Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics (2003). https://doi.org/10.2165/00019053-200321020-00003 3. Sach, T.H., McManus, E., Levell, N.J.: Understanding economic evidence for the prevention and treatment of atopic eczema. Br. J. Dermatol. 181, 707–716 (2019). https://doi.org/10.1111/bjd.17696 4. Ridd, M.J., King, A.J., Le Roux, E., Waldecker, A., Huntley, A.L.: Systematic review of self-management interventions for people with eczema. Br. J. Dermatol. 177(3), 719–734 (2017). https://doi.org/10.1111/bjd.15601 5. Jackson, K., Ersser, S.J., Dennis, H., Farasat, H., More, A.: The eczema education programme: intervention development and model feasibility. J. Eur. Acad. Dermatol. Venereol. 28(7), 949–956 (2014). https://doi.org/10.1111/jdv.12221
|
|